Latest Period
Q2 2026
Security Snapshot
Aligos Therapeutics, Inc. - Common Stock, par value, $0.0001 per share (ALGS) Institutional Ownership
CUSIP: 01626L204
13F Institutional Holders and Ownership History from Q3 2024 to Q2 2026
Institutions Reporting
31
Shares (Excl. Options)
2,292,538
Price
$5.77
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value, $0.0001 per share
- Symbol
- ALGS on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 2,292,538
- Total 13F value
- $13,227,696
- Portfolio coverage rank
- 0%
- Share change
- -482,948
- Value change
- -$3,673,389
- Number of holders
- 31
- Shares outstanding
- 5,646,929
- SEC-reported price per share
- $4.32
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ALGS - Aligos Therapeutics, Inc. - Common Stock, par value, $0.0001 per share is tracked under CUSIP 01626L204.
- 31 institutions reported positions in Q2 2026.
- 7 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 34 to 31 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $20,618,673 to $13,227,696.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 31 institutions filings for Q2 2026.
Security key
01626L204
Latest holder period
Q2 2026
13F holders
31
13D/G owners
7
CIK / CUSIP context first
Open Q2 2026 holders
ALGS full holder history
Aligos Therapeutics, Inc. SEC filings
Aligos Therapeutics, Inc. company facts
Aligos Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 01626L204:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
7
Security
ALGS
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Alyeska Investment Group, L.P. | 10% | $2,809,000 | 530,000 | Alyeska Investment Group, L.P. | 31 Mar 2025 | |||
| Sio Capital Management, LLC | 5.5% | -0.6% | $3,104,058 | -$184,800 | 335,937 | -5.6% | Sio Capital Management, LLC | 31 Dec 2025 |
| BLATT LAWRENCE | 5.6% | +10% | $1,694,982 | +$160,880 | 316,228 | +10% | Lawrence M. Blatt | 16 Jun 2026 |
| Woodline Partners LP | 4.4% | -20% | $2,068,088 | -$430,332 | 239,362 | -17% | Woodline Partners LP | 31 Mar 2026 |
| EcoR1 Capital, LLC | 3.9% | $1,116,360 | 210,634 | EcoR1 Capital, LLC | 31 Mar 2025 | |||
| Adage Capital Management, L.P. | 3.9% | -61% | $1,514,100 | -$829,150 | 210,000 | -35% | Adage Capital Management, L.P. | 30 Jun 2025 |
| ARMISTICE CAPITAL, LLC | 5% | $998,721 | 188,438 | Armistice Capital, LLC | 31 Dec 2024 |
As of 30 Jun 2026, 31 institutional investors reported holding 2,292,538 shares of Aligos Therapeutics, Inc. - Common Stock, par value, $0.0001 per share (ALGS). This represents 41% of the company’s total 5,646,929 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
41%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Deep Track Capital, LP | 7.9% | 444,110 | 0% | 0.04% | $2,562,515 |
| Alyeska Investment Group, L.P. | 7.3% | 412,000 | 0% | 0.01% | $2,377,240 |
| Sio Capital Management, LLC | 5.8% | 327,237 | 0% | 0.32% | $1,888,157 |
| MARSHALL WACE, LLP | 4.4% | 246,579 | -7.7% | 0% | $1,422,761 |
| Woodline Partners LP | 3.1% | 177,362 | 0% | 0% | $1,023,379 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.1% | 175,543 | -1.5% | 0% | $1,012,883 |
| BAKER BROS. ADVISORS LP | 1.5% | 83,055 | 0% | 0% | $479,227 |
| HHLR ADVISORS, LTD. | 1.4% | 76,247 | 0% | 0.05% | $439,945 |
| D. E. Shaw & Co., Inc. | 1.2% | 66,463 | +505% | 0% | $383,491 |
| UBS Group AG | 1.1% | 59,986 | +62% | 0% | $346,119 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.84% | 47,173 | -5.6% | 0% | $272,319 |
| JANE STREET GROUP, LLC | 0.57% | 32,402 | 0% | $186,959 | |
| BlackRock, Inc. | 0.54% | 30,292 | +132% | 0% | $174,785 |
| VANGUARD FIDUCIARY TRUST CO | 0.51% | 28,612 | +0.62% | 0% | $165,091 |
| DIMENSIONAL FUND ADVISORS LP | 0.37% | 21,044 | 0% | $121,424 | |
| Verition Fund Management LLC | 0.33% | 18,887 | 0% | 0% | $108,978 |
| Trexquant Investment LP | 0.22% | 12,339 | 0% | $71,196 | |
| RENAISSANCE TECHNOLOGIES LLC | 0.19% | 10,800 | -89% | 0% | $62,316 |
| Rockefeller Capital Management L.P. | 0.18% | 10,000 | 0% | 0% | $57,700 |
| Federation des caisses Desjardins du Quebec | 0.08% | 4,650 | +389% | 0% | $26,831 |
| Golden State Wealth Management, LLC | 0.05% | 2,674 | 0% | 0% | $15,429 |
| ROYAL BANK OF CANADA | 0.04% | 2,125 | 0% | 0% | $12,000 |
| CITIGROUP INC | 0.03% | 1,808 | 0% | $10,432 | |
| Tower Research Capital LLC (TRC) | 0.01% | 359 | +452% | 0% | $2,071 |
| JPMORGAN CHASE & CO | 0.01% | 344 | -49% | 0% | $1,868 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
8
Latest
Q2 2026
Rows shown
1-8 of 8
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 2,292,538 | $13,227,696 | -$3,673,389 | $5.77 | 31 |
| 2026 Q1 | 2,775,086 | $20,618,673 | -$479,274 | $7.43 | 34 |
| 2025 Q4 | 2,811,051 | $26,190,276 | +$1,301,467 | $9.32 | 39 |
| 2025 Q3 | 2,651,648 | $25,986,937 | +$21,301 | $9.80 | 33 |
| 2025 Q2 | 2,706,213 | $19,511,284 | -$4,851,101 | $7.21 | 37 |
| 2025 Q1 | 3,295,608 | $27,078,858 | +$7,676,587 | $8.25 | 35 |
| 2024 Q4 | 1,619,199 | $64,508,583 | +$11,813,062 | $39.84 | 33 |
| 2024 Q3 | 1,692,019 | $14,651,229 | +$14,572,683 | $8.66 | 27 |